The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Effect of MP0317, a FAP x CD40 DARPin, on safety profile and tumor-localized CD40 activation in a phase 1 study in patients with advanced solid tumors.
 
Neeltje Steeghs
Consulting or Advisory Role - Boehringer Ingelheim (Inst); Bristol-Myers Squibb/Celgene; Ellipses Pharma (Inst); GlaxoSmithKline; GlaxoSmithKline (Inst); Incyte; Incyte (Inst)
Research Funding - Abbvie (Inst); Actuate Therapeutics (Inst); Amgen (Inst); Anaveon (Inst); Ascendis Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CellCentric (Inst); Cogent Biosciences (Inst); Crescendo Biologics (Inst); Deciphera (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); IDRx (Inst); Immunocore (Inst); Incyte (Inst); Janssen (Inst); Kling Biotherapeutics (Inst); Lixte Biotechnology (Inst); Merck KGaA (Inst); Merck Sharp & Dohme (Inst); Merus (Inst); Molecular Partners (Inst); Novartis (Inst); Pfizer (Inst); Revolution Medicines (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Zentalis (Inst)
 
Carlos A. Gomez-Roca
Honoraria - PharmaMar; PSAD
Consulting or Advisory Role - Ellipses Pharma; Macomics
Research Funding - Amgen (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Roche/Genentech
(OPTIONAL) Uncompensated Relationships - ESMO; ESMO; FITC; Oncodistinct
 
Iphigenie Korakis
Travel, Accommodations, Expenses - Roche
 
Eelke Hiddo Gort
No Relationships to Disclose
 
Hilde A.M. De Winter
Employment - Molecular Partners
Stock and Other Ownership Interests - sanofi, argenx, MPAG
 
Nina Stojcheva
Employment - Molecular Partners
Stock and Other Ownership Interests - Molecular Partners
 
Vaia Stavropoulou
Employment - Molecular Partners
Stock and Other Ownership Interests - Molecular Partners
 
Jennifer Krieg
Employment - Molecular Partners
Stock and Other Ownership Interests - Molecular Partners
 
Paul Baverel
Employment - Molecular Partners
Stock and Other Ownership Interests - Molecular Partners
 
Elena Fernandez
Employment - Molecular Partners
Stock and Other Ownership Interests - Molecular Partners AG and Roche
 
Ana Maria Florescu
Employment - Molecular Partners
Stock and Other Ownership Interests - Molecular Partners AG, Sanofi
Travel, Accommodations, Expenses - Velsera
 
Michael T. Stumpp
Employment - Molecular Partners
Leadership - Molecular Partners
Stock and Other Ownership Interests - Molecular Partners
Patents, Royalties, Other Intellectual Property - Molecular Partners
Travel, Accommodations, Expenses - Molecular Partners
 
Philippe Legenne
Employment - Molecular Partners
Stock and Other Ownership Interests - Amgen; Amgen
Honoraria - Johnson & Johnson/Janssen (I)
Travel, Accommodations, Expenses - Molecular Partners
 
Philippe Alexandre Cassier
Consulting or Advisory Role - Boehringer Ingelheim; Brenus Pharma; Bristol-Myers Squibb/Celgene; OSE Immunotherapeutics; Scenic Biotech
Research Funding - Abbvie (Inst); Adlai Nortye (Inst); Alligator Bioscience (Inst); Amgen (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); C4 Therapeutics (Inst); Daiichi Sankyo/UCB Japan (Inst); Debiopharm Group (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Innate Pharma (Inst); ITeos Therapeutics (Inst); Janssen (Inst); Lilly (Inst); Loxo (Inst); Merck Sharp & Dohme (Inst); Molecular Partners (Inst); Novartis (Inst); OSE Immunotherapeutics (Inst); Pierre Fabre (Inst); Relay Therapeutics (Inst); Roche/Genentech (Inst); Sotio (Inst); Taiho Pharmaceutical (Inst); Tango Therapeutics (Inst); Toray Industries (Inst); Transgene (Inst)
Travel, Accommodations, Expenses - Novartis; OSE Immunotherapeutics; Roche
(OPTIONAL) Uncompensated Relationships - ReACT Therapeutics